Physician profile
Peter A Krause
NPI 1073534442
$3,768.05
in general payments reported to CMS, 2019-2025
23 companies · $889 in 2025
The $889 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $26.11 · 2021: $251 · 2022: $503 · 2023: $816 · 2024: $886 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,591.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $658.93 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $422.86 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $365.76 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $347.62 | 2023-2025 | |
| Merz North America, INC. | $293.37 | 2021-2025 | Xeomin |
| Bayer Healthcare Pharmaceuticals INC. | $289.58 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $283.41 | 2019-2022 | |
| Glaxosmithkline, LLC. | $277.95 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Galderma Laboratories, L.P. | $244.25 | 2021-2024 | Dysport |
| Pfizer INC. | $215.57 | 2019-2025 | |
| Revance Therapeutics, INC. | $71.10 | 2025 | Daxxify |
| Xeris Pharmaceuticals, INC. | $55.17 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $52.23 | 2022-2023 | Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $39.34 | 2023 | Quviviq |
| Allergan, INC. | $29.47 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $28.71 | 2025 | Veozah |
| Exact Sciences Corporation | $15.07 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $14.82 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.41 | 2022 | |
| Mannkind Corporation | $12.78 | 2019 | |
| Sanofi Pasteur INC. | $12.41 | 2019 | |
| Dexcom, INC. | $12.32 | 2021 | |
| Amarin Pharma, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Krause listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.